Ironwood Pharmaceuticals
MA - Boston
Pharmaceutical1 H-1B visas (FY2023)Focus: Small Molecules
Ironwood Pharmaceuticals is a life sciences company focused on Small Molecules.
Neurology
Open Jobs
5
Products & Portfolio (2)
DUZALLO
allopurinol; lesinurad
Peak
ORAL · TABLET
Allopurinol acts on purine catabolism, without disrupting the biosynthesis of purines. It reduces the production of uric acid by inhibiting the biochemical reactions immediately preceding its formation. Allopurinol is a structural analogue of the natural purine base, hypoxanthine. It is an inhibitor of xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and of xanthine to uric acid, the end product of purine metabolism in man. Allopurinol is metabolized to the corresponding xanthine analogue, oxipurinol (alloxanthine), which also is an inhibitor of xanthine oxidase. [Allopurinol-ROS] It has been shown that reutilization of both hypoxanthine and xanthine for nucleotide and nucleic acid synthesis is markedly enhanced when their oxidations are inhibited by allopurinol and oxipurinol. This reutilization does not disrupt normal nucleic acid anabolism, however, because feedback inhibition is an integral part of purine biosynthesis. As a result of xanthine oxidase inhibition, the serum concentration of hypoxanthine plus xanthine in patients receiving allopurinol tablets for treatment of hyperuricemia is usually in the range of 0.3 to 0.4 mg/dL compared to a normal level of approximately 0.15 mg/dL. A maximum of 0.9 mg/dL of these oxypurines has been reported when the serum urate was lowered to less than 2 mg/dL by high doses of allopurinol tablets. These values are far below the saturation levels at which point their precipitation would be expected to occur (above 7 mg/dL). The renal clearance of hypoxanthine and xanthine is at least 10 times greater than that of uric acid. The increased xanthine and hypoxanthine in the urine have not been accompanied by problems of nephrolithiasis. Xanthine crystalluria has been reported in only three patients. Two of the patients had Lesch-Nyhan syndrome, which is characterized by excessive uric acid production combined with a deficiency of the enzyme, hypoxanthineguanine phosphoribosyltransferase (HGPRTase). This enzyme is required for the conversion of hypoxanthine, xanthine, and guanine to their respective nucleotides. The third patient had lymphosarcoma and produced an extremely large amount of uric acid because of rapid cell lysis during chemotherapy. Allopurinol is approximately 90% absorbed from the gastrointestinal tract. Peak plasma levels generally occur at 1.5 hours and 4.5 hours for allopurinol and oxipurinol respectively, and after a single oral dose of 300 mg allopurinol tablets, maximum plasma levels of about 3 mcg/mL of allopurinol and 6.5 mcg/mL of oxipurinol are produced. Approximately 20% of the ingested allopurinol is excreted in the feces. Because of its rapid oxidation to oxipurinol and a renal clearance rate approximately that of glomerular filtration rate, allopurinol has a plasma half-life of about 1 to 2 hours. Oxipurinol, however, has a longer plasma half-life (approximately 15 hours) and therefore effective xanthine oxidase inhibition is maintained over a
leukemialymphoma
2017
0
ZURAMPIC
lesinurad
Peak
ORAL · TABLET
2015
0
Pipeline & Clinical Trials
Ispaghula
ConstipationClinical Trials (1)
NCT02144376MRI and Microbiota Analysis in Constipation
N/A7 g Ispaghula
HealthyClinical Trials (1)
NCT01805999Ispaghula and Colonic Water Content
N/AVirtual Reality
Irritable Bowel Syndrome With ConstipationMicrogestin®
Healthy VolunteersClinical Trials (1)
NCT03856970Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers
Phase 1IW-3300
Healthy VolunteersClinical Trials (1)
NCT05188261A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers
Phase 1IW-3300
Healthy VolunteersClinical Trials (1)
NCT05362695A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects
Phase 1Linaclotide
Functional ConstipationIW-3300 rectal foam
Interstitial CystitisClinical Trials (1)
NCT05740007A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
Phase 2Linaclotide
Irritable Bowel Syndrome With ConstipationClinical Trials (1)
NCT02559206Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Phase 2Linaclotide
Functional ConstipationClinical Trials (1)
NCT04110145Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation
Phase 2Phase 2
Clinical Trials (1)
NCT02637557A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)
Phase 2MD-0727
HypercholesterolemiaClinical Trials (1)
NCT00404001Study of Oral MD-0727 Administered to Patients With Primary Hypercholesterolemia
Phase 2IW-9179
Diabetic GastroparesisClinical Trials (1)
NCT02289846Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
Phase 2Phase 2
Clinical Trials (1)
NCT03931785A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome
Phase 2Linaclotide 145 micrograms
Opioid-Induced ConstipationClinical Trials (1)
NCT02270983Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain
Phase 2IW-3718
Gastroesophageal RefluxClinical Trials (1)
NCT02030925Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors
Phase 2MD-1100 Acetate
ConstipationClinical Trials (1)
NCT00306748Phase 2 Study of MD-1100 Acetate Administered for 14 Days to Patients Meeting Criteria for Chronic Constipation
Phase 2IW-6118
HealthyClinical Trials (1)
NCT01107236Study to Evaluate Efficacy and Safety of IW-6118 in Patients Undergoing Third Molar Extraction
Phase 2MD-1100 Acetate
Irritable Bowel SyndromeClinical Trials (1)
NCT00258193Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS
Phase 2Linaclotide Acetate
Irritable Bowel Syndrome With ConstipationClinical Trials (1)
NCT00460811Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Phase 2Phase 2
Clinical Trials (1)
NCT02559570A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)
Phase 2linaclotide acetate
Chronic ConstipationClinical Trials (1)
NCT00402337Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation
Phase 2IW-9179
DyspepsiaClinical Trials (1)
NCT01712412Phase 2a Study of IW-9179 to Treat Functional Dyspepsia
Phase 2Linaclotide Dose A
Irritable Bowel Syndrome With ConstipationClinical Trials (1)
NCT02559817A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation
Phase 2Linaclotide
Functional ConstipationPhase 3
Clinical Trials (1)
NCT03573908A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Phase 3Linaclotide 290 micrograms
Irritable Bowel Syndrome Characterized by ConstipationClinical Trials (1)
NCT00948818Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation
Phase 3Phase 3
Clinical Trials (1)
NCT03561883Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
Phase 3Matching Placebo
Chronic ConstipationClinical Trials (1)
NCT00730015Trial of Linaclotide in Patients With Chronic Constipation
Phase 3Phase 3
Linaclotide
Chronic ConstipationClinical Trials (1)
NCT00765999An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
Phase 3Phase 3
Clinical Trials (1)
NCT03561090A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
Phase 3Linaclotide
Chronic Idiopathic ConstipationClinical Trials (1)
NCT02291679Trial of Linaclotide in Patients With Chronic Idiopathic Constipation
Phase 3Irritable Bowel Syndrome with Constipation
Irritable Bowel Syndrome With ConstipationLinaclotide or Matching Placebo
Irritable Bowel Syndrome With ConstipationClinical Trials (1)
NCT00938717Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Phase 3Linaclotide
Irritable Bowel Syndrome With ConstipationClinical Trials (1)
NCT00730171An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
Phase 3Linaclotide 290 micrograms
Chronic ConstipationClinical Trials (1)
NCT01642914Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating
Phase 3Linaclotide 290 micrograms
Chronic ConstipationClinical Trials (1)
NCT00765882Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation
Phase 3Linaclotide
Functional Constipation (FC)Phase 4
Clinical Trials (1)
NCT02837783A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)
Phase 4Linaclotide
Irritable Bowel Syndrome With ConstipationClinical Trials (1)
NCT02590432An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
Phase 4Lesinurad
GoutClinical Trials (1)
NCT03226899A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
Phase 4Open Jobs (5)
Clinical Operations Lead, Development Operations
Basel, Switzerland
Supply Chain2w ago
Director, Global Regulatory Affairs (GRA) - CMC
Boston, Massachusetts, United States
Regulatory Affairs1mo ago
Senior Medical Director, Clinical Development
Boston, Massachusetts, United States
Clinical Development2mo ago
$264K - $277K/yr
Senior Director, Medical Writing
Boston, Massachusetts, United States
Regulatory Affairs2mo ago
$239K - $279K/yr
Associate Director, Global Patient Safety Operations
Boston, Massachusetts, United States
60750 Global Patient Safety2mo ago
$167K - $200K/yr
Interview Prep Quick Facts
Portfolio: 2 approved products, 36 clinical trials
H-1B (2023): 1 approval
Open Roles: 5 active jobs
Portfolio Health
Peak2 (100%)
2 total products
Hiring Trend
Stable
5
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub